Pharmacokinetic Assessment of Continuous Infusion Ceftolozane/Tazobactam for Drug-Resistant Pseudomonas aeruginosa Left Ventricular Assist Device Driveline Infection

Abstract

Conclusion. Our findings suggest that the model can reasonably identify patients whose infections would be likely to be covered by cefazolin. Further, the majority of patients would have been covered by a narrower spectrum antibiotics than what they received. Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the NIH under Award Number R01AI116975. Disclosures. All authors: No reported disclosures.

Topics

    0 Figures and Tables

      Download Full PDF Version (Non-Commercial Use)